Comparative Pharmacology
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus DIAPID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DDAVP NEEDS NO REFRIGERATION versus DIAPID.
DDAVP (NEEDS NO REFRIGERATION) vs DIAPID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that acts on V2 receptors in renal collecting ducts to increase water reabsorption and concentrate urine. It also raises plasma levels of factor VIII and von Willebrand factor via V2 receptor activation on endothelial cells.
Diapid (lypressin) is a synthetic analog of vasopressin that acts as an antidiuretic by increasing water reabsorption in the renal collecting ducts via V2 receptor activation. It also has mild vasopressor activity via V1 receptor stimulation.
1-2 mg orally twice daily for central diabetes insipidus; intranasal 10-40 mcg/day in 1-3 divided doses; IV/SC 0.5-2 mcg/day in divided doses for diabetes insipidus.
Intravenous bolus of 20 mg followed by 20-40 mg every 2-4 hours as needed. Maximum single dose: 80 mg.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours for intravenous and oral routes; increased to 3-5 hours in patients with renal impairment.
Terminal elimination half-life is 1.5-3 hours; clinically significant in patients with renal impairment, requiring dose adjustment
Primarily renal (approximately 60-70% excreted unchanged in urine); minimal biliary/fecal elimination (<5%).
Primarily renal excretion as unchanged drug (80-90%); minor biliary/fecal elimination (<10%)
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog